Floyd F. Petersen Sells 500 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Stock

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Director Floyd F. Petersen sold 500 shares of the company’s stock in a transaction dated Wednesday, May 1st. The shares were sold at an average price of $41.67, for a total transaction of $20,835.00. Following the transaction, the director now owns 78,833 shares in the company, valued at approximately $3,284,971.11. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Amphastar Pharmaceuticals Stock Performance

Shares of AMPH opened at $42.46 on Friday. Amphastar Pharmaceuticals, Inc. has a 1 year low of $35.93 and a 1 year high of $67.66. The company has a debt-to-equity ratio of 0.92, a current ratio of 2.17 and a quick ratio of 1.70. The stock’s fifty day moving average price is $43.48 and its two-hundred day moving average price is $50.74. The firm has a market cap of $2.07 billion, a PE ratio of 16.46, a PEG ratio of 1.01 and a beta of 0.85.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its quarterly earnings data on Wednesday, February 28th. The company reported $0.81 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.84 by ($0.03). The firm had revenue of $178.11 million during the quarter, compared to the consensus estimate of $174.90 million. Amphastar Pharmaceuticals had a net margin of 21.34% and a return on equity of 26.95%. On average, equities research analysts forecast that Amphastar Pharmaceuticals, Inc. will post 3.41 EPS for the current year.

Analysts Set New Price Targets

A number of research firms recently weighed in on AMPH. Needham & Company LLC reaffirmed a “hold” rating on shares of Amphastar Pharmaceuticals in a research note on Wednesday, April 10th. StockNews.com cut shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, February 29th. Finally, JPMorgan Chase & Co. initiated coverage on shares of Amphastar Pharmaceuticals in a report on Tuesday, March 5th. They set an “overweight” rating and a $60.00 price objective for the company. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, Amphastar Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $66.00.

Institutional Investors Weigh In On Amphastar Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. YHB Investment Advisors Inc. bought a new position in shares of Amphastar Pharmaceuticals in the first quarter valued at approximately $27,000. McGlone Suttner Wealth Management Inc. purchased a new stake in Amphastar Pharmaceuticals in the fourth quarter valued at approximately $28,000. Principal Securities Inc. bought a new stake in Amphastar Pharmaceuticals during the fourth quarter valued at approximately $34,000. China Universal Asset Management Co. Ltd. grew its stake in Amphastar Pharmaceuticals by 99.2% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,261 shares of the company’s stock worth $58,000 after buying an additional 628 shares in the last quarter. Finally, Quadrant Capital Group LLC increased its holdings in shares of Amphastar Pharmaceuticals by 27.8% in the 4th quarter. Quadrant Capital Group LLC now owns 1,026 shares of the company’s stock worth $63,000 after buying an additional 223 shares during the last quarter. Institutional investors own 65.09% of the company’s stock.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.